Literature DB >> 12499902

Hypereosinophilia as a presenting sign of acute graft-versus-host disease after allogeneic bone marrow transplantation.

D McNeel1, M T Rubio, G Damaj, J F Emile, C Belanger, B Varet, N Brousse, O Hermine, A Buzyn.   

Abstract

The authors report two cases of hypereosinophilia as the major presenting sign of acute graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT). Tissue biopsies of the skin, salivary gland, gut, and liver showed evidence of acute GVHD (aGVHD). In one case, further investigations have been performed. Elevated levels of interleukin (IL)-5 and soluble IL-2 receptor were found in the blood, and skin biopsy specimens demonstrated high levels of IL-5 messenger ribonucleic acid (mRNA). In contrast, skin biopsy specimens from other patients with aGVHD but without eosinophilia were negative for IL-5 mRNA. The authors also demonstrated the presence of IL-4 and interferon(IFN)-gamma mRNA within the same skin biopsy specimen, suggesting that this case of aGVHD was mediated by both Th1 and Th2 cell type. These two patients were treated by glucocorticoids with resolution of the hypereosinophilia and the symptoms of GVHD. The authors briefly discuss the possible mechanisms of this hypereosinophilia with respect to aGVHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12499902     DOI: 10.1097/00007890-200212270-00028

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

1.  Expression of CD27 on peripheral CD4+ T-lymphocytes correlates with the development of severe acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Hitoshi Yoshida; Tetsuo Maeda; Jun Ishikawa; Shinya Inoue; Hitomi Matsunaga; Satoru Kosugi; Masamichi Shiraga; Kenji Oritani; Yuzuru Kanakura; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

2.  A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.

Authors:  Douglas G McNeel; Thomas A Gardner; Celestia S Higano; Philip W Kantoff; Eric J Small; Mark H Wener; Robert B Sims; Todd DeVries; Nadeem A Sheikh; Robert Dreicer
Journal:  Cancer Immunol Res       Date:  2014-09-04       Impact factor: 11.151

3.  Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.

Authors:  Hiroki Hosoi; Shogo Murata; Toshiki Mushino; Akinori Nishikawa; Takashi Sonoki
Journal:  Ann Hematol       Date:  2020-08-21       Impact factor: 3.673

4.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Authors:  Paul A Carpenter; Carrie L Kitko; Sharon Elad; Mary E D Flowers; Juan C Gea-Banacloche; Jörg P Halter; Flora Hoodin; Laura Johnston; Anita Lawitschka; George B McDonald; Anthony W Opipari; Bipin N Savani; Kirk R Schultz; Sean R Smith; Karen L Syrjala; Nathaniel Treister; Georgia B Vogelsang; Kirsten M Williams; Steven Z Pavletic; Paul J Martin; Stephanie J Lee; Daniel R Couriel
Journal:  Biol Blood Marrow Transplant       Date:  2015-03-31       Impact factor: 5.742

5.  Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation.

Authors:  Skylar Klager; Mario E Lacouture; Margaret Hannum; Sean M Devlin; Molly Maloy; Melissa Pulitzer; Ann A Jakubowski; Alina Markova
Journal:  Biol Blood Marrow Transplant       Date:  2019-07-12       Impact factor: 5.742

6.  National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.

Authors:  Kristin Baird; Seth M Steinberg; Lana Grkovic; Drazen Pulanic; Edward W Cowen; Sandra A Mitchell; Kirsten M Williams; Manuel B Datiles; Rachel Bishop; Carol W Bassim; Jacqueline W Mays; Dean Edwards; Kristen Cole; Daniele N Avila; Tiffany Taylor; Amanda Urban; Galen O Joe; Leora E Comis; Ann Berger; Pamela Stratton; Dan Zhang; James H Shelhamer; Juan C Gea-Banacloche; Claude Sportes; Daniel H Fowler; Ronald E Gress; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2013-01-20       Impact factor: 5.742

Review 7.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Thomas B Nutman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

8.  Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome.

Authors:  Fabian Beier; Klaus Arbter; Nicolai A Kittan; Reinhard Andreesen; Stefan W Krause; Ernst Holler; Gerhard C Hildebrandt
Journal:  Mol Clin Oncol       Date:  2013-09-25

9.  Eosinophils in the blood of hematopoietic stem cell transplanted patients are activated and have different molecular marker profiles in acute and chronic graft-versus-host disease.

Authors:  Julia Cromvik; Marianne Johnsson; Krista Vaht; Jan-Erik Johansson; Christine Wennerås
Journal:  Immun Inflamm Dis       Date:  2014-07-07

10.  Retrospective Study of Incidence and Prognostic Significance of Eosinophilia after Allogeneic Hematopoietic Stem Cell Transplantation: Influence of Corticosteroid Therapy.

Authors:  Wataru Yamamoto; Eriko Ogusa; Kenji Matsumoto; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.